NCT00138879View on ClinicalTrials.gov

Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients

CompletedOBSERVATIONAL
Enrollment

54

Participants

Timeline

Start Date

May 31, 2003

Study Completion Date

June 30, 2005

Conditions
Crohn's DiseaseShort Bowel SyndromeMalabsorption SyndromesCeliac Disease
Trial Locations (1)

HA1 3JX

St Mark's Hospital, London

All Listed Sponsors
lead

St Mark's Hospital Foundation

OTHER

NCT00138879 - Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients | Biotech Hunter | Biotech Hunter